We are live on ! Find out more
IOBT

IO Biotech
IOBT

Delisted

IOBT was delisted on the 6th of April, 2026.

Back to rankings

21 hedge funds and large institutions have $41.6M invested in IO Biotech in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

17% more funds holding

Funds holding: 18 → 21 (+3)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.41% less ownership

Funds ownership: 53.62% → 53.21% (-0.41%)

42% less capital invested

Capital invested by funds: $72.2M → $41.6M (-$30.6M)

Holders
21
Holders Change
+3
Holders Change %
+16.67%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$371K
2
Victory Capital Management
Victory Capital Management
Texas
+$162K
3
PVH
Psagot Value Holdings
Israel
+$151K
4
Citadel Advisors
Citadel Advisors
Florida
+$103K
5
BCM
Bridgeway Capital Management
Texas
+$77.5K

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$1.36M
2
Millennium Management
Millennium Management
New York
-$29.3K
3
UBS Group
UBS Group
Switzerland
-$10K
4
Morgan Stanley
Morgan Stanley
New York
-$7.6K
5
Citigroup
Citigroup
New York
-$5K

IOBT Hedge Fund Activity: Q3 2022 in Review

21 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q3 2022, worth a combined $41.6M — down 42% from $72.2M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new IOBT positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Newtyn Management, opening a new position worth an estimated $371K. The largest seller was Soleus Capital Management, cutting an estimated $1.36M.

  • 21 institutional investors held IO Biotech (IOBT) as of Q3 2022, up from 18 in Q2 2022.
  • Funds reported $41.6M of IO Biotech stock for Q3 2022, down 42% quarter-over-quarter.
  • 6 funds opened new IO Biotech positions in Q3 2022 and 3 closed out, a net change of +3 holders.
  • The largest IO Biotech buyer in Q3 2022 was Newtyn Management, an estimated $371K added.
  • The largest IO Biotech seller in Q3 2022 was Soleus Capital Management, an estimated $1.36M sold.

Based on aggregated 13F filings for Q3 2022.